| Bioactivity | Etiprednol dicloacetate (BNP 166) is an anti-inflammatory agent. Etiprednol dicloacetate inhibits eosinophil accumulation. Etiprednol dicloacetate can be used in the research of inflammatory airway diseases, such as asthma[1][2]. |
| Invitro | Etiprednol dicloacetate (1 nM-1 μM) inhibits LPS-induced TNF-α production by human blood[1]. |
| In Vivo | Etiprednol dicloacetate (0-100 μg/kg, intranasal inhalation) attenuates peribronchial eosinophilia in the lung of the allergen sensitized and challenged rats[1].Etiprednol dicloacetate (0.1 μg/kg, intranasal inhalation) inhibits eosinophil accumulation in rats (antigen-induced airway eosinophil infiltration)[3].Etiprednol dicloacetate (0-20 mg/kg, p.o., 28 days) is well tolerated in rats and dogs[2]. Animal Model: |
| Name | Etiprednol dicloacetate |
| CAS | 199331-40-3 |
| Formula | C24H30Cl2O6 |
| Molar Mass | 485.40 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. István Kurucz, et al. Potency and specificity of the pharmacological action of a new, antiasthmatic, topically administered soft steroid, etiprednol dicloacetate (BNP-166). J Pharmacol Exp Ther. 2003 Oct;307(1):83-92. [2]. A Miklós, et al. 28-day oral toxicity study with soft corticosteroid BNP-166 in rats and dogs, followed by a 14-day recovery period. Pharmazie. 2002 Feb;57(2):142-6. [3]. I Kurucz, et al. Anti-inflammatory effect and soft properties of etiprednol dicloacetate (BNP-166), a new, anti-asthmatic steroid. Pharmazie. 2004 May;59(5):412-6. |
Etiprednol dicloacetate
CAS: 199331-40-3 F: C24H30Cl2O6 W: 485.40
Etiprednol dicloacetate (BNP 166) is an anti-inflammatory agent. Etiprednol dicloacetate inhibits eosinophil accumulatio
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.